Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
HLX-53
i
Other names:
HLX-53, HLX53, HLX 53
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
News
Trials
Company:
Fosun Pharma
Drug class:
TIGIT inhibitor
Related drugs:
‹
AB154 (5)
BGB-A1217 (5)
RG6058 (3)
HB0030 (1)
EOS-448 (1)
AZD2936 (1)
IBI-939 (1)
MK-7684 (1)
ASP8374 (0)
AUR-106 (0)
BAT6005 (0)
COM902 (0)
DSP502 (0)
HB0036 (0)
JS006 (0)
MG1131 (0)
PH-804 TME (0)
PM1022 (0)
SEA-TGT (0)
SL-9258 (0)
Undisclosed TIGIT ETB (0)
ZG005 (0)
ZGGS15 (0)
M6223 (0)
MPH-313 (0)
AK127 (0)
AB308 (0)
BMS-986207 (0)
MK-7684A (0)
AB154 (5)
BGB-A1217 (5)
RG6058 (3)
HB0030 (1)
EOS-448 (1)
AZD2936 (1)
IBI-939 (1)
MK-7684 (1)
ASP8374 (0)
AUR-106 (0)
BAT6005 (0)
COM902 (0)
DSP502 (0)
HB0036 (0)
JS006 (0)
MG1131 (0)
PH-804 TME (0)
PM1022 (0)
SEA-TGT (0)
SL-9258 (0)
Undisclosed TIGIT ETB (0)
ZG005 (0)
ZGGS15 (0)
M6223 (0)
MPH-313 (0)
AK127 (0)
AB308 (0)
BMS-986207 (0)
MK-7684A (0)
›
Associations
News
Trials
Filter by
Latest
8ms
A Study to Explore the Reasonable Dosage and Evaluate the Efficacy, Safety and Tolerability of HLX10 and HLX04 With or Without HLX53 in Untreated, Locally Advanced or Metastatic Hepatocellular Carcinoma Patients. (clinicaltrials.gov)
P2, N=117, Not yet recruiting, Shanghai Henlius Biotech
8 months ago
New P2 trial • Metastases
|
Hetronifly (serplulimab) • HLX-53 • Hanbeitai (bevacizumab biosimilar)
8ms
A Phase I Clinical Study of HLX53 in Advanced/Metastatic Solid Tumors (clinicaltrials.gov)
P1, N=12, Active, not recruiting, Shanghai Henlius Biotech | Recruiting --> Active, not recruiting | N=20 --> 12 | Trial primary completion date: Aug 2024 --> Dec 2024
8 months ago
Enrollment closed • Enrollment change • Trial primary completion date • Metastases
|
HLX-53
over1year
A Phase I Clinical Study of HLX53 in Advanced/Metastatic Solid Tumors or Lymphoma (clinicaltrials.gov)
P1, N=20, Recruiting, Shanghai Henlius Biotech | Not yet recruiting --> Recruiting
over 1 year ago
Enrollment open • Metastases
|
TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2)
|
HLX-53
over2years
A Phase I Clinical Study of HLX53 in Advanced/Metastatic Solid Tumors or Lymphoma (clinicaltrials.gov)
P1, N=20, Not yet recruiting, Shanghai Henlius Biotech
over 2 years ago
New P1 trial
|
TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2)
|
HLX-53
Share via
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login